Drug Profile
Survodutide - Boehringer Ingelheim
Alternative Names: BI-456906; BI-456909Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Boehringer Ingelheim; Zealand Pharma
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 13 Mar 2024 Boehringer Ingelheim plans a phase III trial for Obesity and Non-Alcoholic Steatohepatitis in March 2024 (SC) (NCT06309992 )
- 04 Mar 2024 Boehringer Ingelheim initiates a phase I trial for Obesity (In volunteers) (SC, Injection) (NCT06200467)
- 26 Feb 2024 Efficacy and adverse events data from a phase II trial in Non-alcoholic Steatohepatitis released by Zealand Pharma